Creators of clinical trial modeling and simulation approaches soon could have a pathway for multiple sponsors to use them, potentially streamlining drug development time and costs.
Officials in the US Food and Drug Administration’s Office of Generic Drugs are considering creating model master files, which would be similar to the drug master file (DMF) system that has been in place for years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?